Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 90,600 shares, a growth of 9.7% from the November 15th total of 82,600 shares. Based on an average daily trading volume, of 58,300 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.3% of the company's stock are sold short.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on IKNA. Wedbush reissued a "neutral" rating and set a $2.00 price objective on shares of Ikena Oncology in a report on Thursday, November 7th. HC Wainwright reissued a "buy" rating and issued a $4.00 price objective on shares of Ikena Oncology in a report on Monday, November 11th.
Get Our Latest Stock Report on Ikena Oncology
Ikena Oncology Price Performance
Shares of NASDAQ:IKNA traded down $0.01 on Friday, reaching $1.65. The company's stock had a trading volume of 79,810 shares, compared to its average volume of 231,428. Ikena Oncology has a 52-week low of $1.22 and a 52-week high of $2.32. The stock's 50-day moving average is $1.71 and its two-hundred day moving average is $1.70. The stock has a market capitalization of $79.63 million, a P/E ratio of -1.34 and a beta of 0.49.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.08. Equities analysts forecast that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC bought a new position in shares of Ikena Oncology in the second quarter valued at approximately $30,000. BBR Partners LLC bought a new stake in shares of Ikena Oncology during the second quarter worth $33,000. AQR Capital Management LLC bought a new stake in Ikena Oncology during the 2nd quarter worth about $36,000. FMR LLC increased its stake in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company's stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ikena Oncology during the second quarter worth approximately $75,000. Institutional investors own 75.00% of the company's stock.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
